Chronic Peripheral Administration of Kappa-Opioid Receptor Antagonist Advances Puberty Onset Associated with Acceleration of Pulsatile Luteinizing Hormone Secretion in Female Rats

Tatsuo NAKAHARA¹), Yoshihisa UENOYAMA²), Akira IWASE¹), Shinya OISHI³), Sho NAKAMURA⁴), Shiori MINABE²), Youki WATANABE²), Chikaya DEURA²), Taro NOGUCHI³), Nobutaka FUJII³), Fumitaka KIKKAWA¹), Kei-ichiro MAEDA⁴) and Hiroko TSUKAMURA²)

¹)Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan
²)Graduate School of Bioagricultural Sciences, Nagoya University, Nagoya 464-8601, Japan
³)Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8501, Japan
⁴)Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo 113-8657, Japan

Abstract. Puberty in mammals is timed by an increase in gonadotropin-releasing hormone (GnRH) secretion. Previous studies have shown involvement of the two neuropeptides, kisspeptin and neurokinin B (NKB), in controlling puberty onset. Little is known about the role of the other key neuropeptide, dynorphin, in controlling puberty onset, although these three neuropeptides colocalize in the arcuate kisspeptin neurons. The arcuate kisspeptin neuron, which is also referred to as the KNDy neuron, has recently been considered to play a role as an intrinsic source of the GnRH pulse generator. The present study aimed to determine if attenuation of inhibitory dynorphin-kappa-opioid receptor (KOR) signaling triggers the initiation of puberty in normal developing female rats. The present study also determined if stimulatory NKB-neurokinin 3 receptor (NK3R) signaling advances puberty onset. Female Wistar-Imamichi rats were weaned and intraperitoneally implanted with osmotic minipumps filled with nor-binaltorphimine (nor-BNI), a KOR antagonist, or senktide, a NK3R agonist, at 20 days of age. Fourteen days of intraperitoneal infusion of nor-BNI or senktide advanced puberty onset, manifested as vaginal opening and the first vaginal estrus in female rats. Frequent blood sampling showed that nor-BNI significantly increased luteinizing hormone (LH) pulse frequency at 29 days of age compared with vehicle-treated controls. Senktide tended to increase this frequency, but its effect was not statistically significant. The present results suggest that the inhibitory input of dynorphin-KOR signaling plays a role in the prepubertal restraint of GnRH/LH secretion in normal developing female rats and that attenuation of dynorphin-KOR signaling and increase in NKB-NK3R signaling trigger the onset of puberty in female rats.

Key words: GPR54, Metastin, Sexual maturation

Puberty, a complex sequence of maturational events, is driven by the activation of the hypothalamic-pituitary-gonadal axis. The secretion of gonadotropin-releasing hormone (GnRH) from the hypothalamus represents the first well-known step in the initiation of puberty [1, 2]. GnRH-induced gonadotropin secretion from the anterior pituitary stimulates gametogenesis and gonadal steroidogenesis in the ovary [3]. An increase in the circulating level of estrogen leads to opening of the vaginal cavity as a sign of puberty onset in female rodents, and then female rodents consequently show estrous cyclicity. The potential mechanism underlying pubertal increase in GnRH secretion has been sought by pinpointing the loss-of-functional mutations of genes coding kisspeptin, neurokinin B (NKB) or their cognate receptors, GPR54 and neurokinin 3 receptor (NK3R), in patients with hypogonadotropic hypogonadism [4–8]. Previous rodent studies showed pubertal increases in kisspeptin and NKB expression in the hypothalamus [9–12], and central administration of kisspeptin advanced puberty onset in normal developing female rats [13]. Central administration of senktide, an NK3R agonist, induced puberty onset in 5 of 11 underfed female rats [12], suggesting that NKB-NK3R signaling at least partly contributes to the pubertal increase in GnRH secretion in underfed rats. On the other hand, central administration of SB222200, an NK3R antagonist, failed to affect puberty onset in normally fed rats [12]. This inconsistency in the involvement of NKB-NK3R signaling in puberty onset led us to evaluate the roles of NKB-NK3R signaling in puberty onset in normally fed developing female rats.

Dynorphin, a member of the endogenous opioids derived from the prodynorphin gene [14], has emerged as a key inhibitory neuropeptide in controlling reproductive function [15–18]. Dynorphin neurons are abundantly distributed in several regions of the hypothalamus [19, 20] including the ARC, where dynorphin is coexpressed in a group of neurons with kisspeptin and NKB in mice [21], rats [22], sheep [23] and goats [16]. The group of ARC neurons, referred to as KNDy neurons [23], was recently considered to play a critical role in pulsatile GnRH secretion. A series of studies recording the
chronic multiple unit activity (MUA) in close proximity to KNDy neurons in the ARC of goats demonstrated that periodic bursts (MUA volleys) were accompanied by luteinizing hormone (LH) pulses with regular intervals [16, 24], suggesting that ARC KNDy neurons may be the intrinsic source of the GnRH pulse generator and that the MUA volleys may represent the rhythmic release of kisspeptin from the KNDy neurons. Central administration of NKB or a synthetic antagonist for kappa-opioid receptor (KOR), the preferred receptor for dynorphin, facilitated the MUA volleys [16]. Combined with the fact that kisspeptin governs GnRH/LH secretion in a variety of mammals [24–29], these findings suggest that dynorphin and NKB expressed in ARC KNDy neurons are involved in the process of generating the rhythmic discharge of kisspeptin that drives pulsatile GnRH/LH secretion. More specifically, dynorphin and NKB have an inhibitory and stimulatory role, respectively, in generating pulsatile GnRH/LH secretion [16].

To date, no mutation of a gene coding dynorphin or KOR has been reported in human. Little is known about the involvement of dynorphin-KOR signaling in the regulation of the pubertal increase in GnRH/LH pulses. Our recent study indicated that central administration of the KOR antagonist facilitates pulsatile LH secretion in estrogen-treated ovariectomized rats but not ovariectomized animals, suggesting that dynorphin is involved in mediating the negative feedback action of estrogen on GnRH/LH secretion in female rats [18]. Taken together with estrogen-dependent suppression of LH secretion in prepubertal rats [10], we hypothesized that dynorphin-KOR signaling plays a central and critical role in the negative regulation of the prepubertal restraint GnRH/LH secretion in rats. A single intracerebroventricular injection of KOR antagonist had no effect on LH secretion in prepubertal female rats [30], suggesting that dynorphin-KOR signaling had lower importance with regard to the prepubertal restraint of LH secretion in rats. Chronic KOR-antagonizing action, however, may be required for advancement of puberty onset in female rats.

The present study aimed to determine the roles of dynorphin-KOR and NKB-NK3R signaling in initiation of puberty in normal developing female rats. To this end, we examined the effects of chronic peripheral administration of KOR antagonist and NK3R agonist on puberty onset and LH pulses in peripubertal female rats to evaluate if attenuation of dynorphin-KOR signaling triggers puberty onset and if an increase in NKB-NK3R signaling advances puberty onset. Peripheral infusion was chosen because of the possibility that these treatments in patients with a disruption of normal pulsatile GnRH/LH secretion may be therapeutic.

Materials and Methods

Animals

Wistar-Imamichi strain rats were kept under a 14:10 h light/dark cycle (lights on at 0500 h) at 22 ± 2°C with free access to food (CE-2; CLEA Japan, Tokyo, Japan) and water. Female rats (8–9 weeks old of age) having at least two consecutive regular 4-day estrus cycles were mated with males overnight on the day of proestrus, and then the pregnant females were housed individually. The day on which the first copulation occurred was designated pregnancy day 0. The litter size was adjusted to eight on day 1 to minimize the growth variation within litters. The pups were weaned on day 20. Surgical procedures were performed under anesthesia with inhaled isoflurane or a ketamine-xylazine mixture.

The care of the animals and all of the experimental procedures used in these experiments were approved by the Committee on Animal Experiments of the Graduate School of Bioagricultural Sciences, Nagoya University.

Effects of chronic intraperitoneal administration of KOR antagonist or NK3R agonist on puberty onset

Female rats (n = 6 per treatment group) were weaned on day 20 and randomly assigned to one of three treatment groups. Alzet osmotic minipumps (model 2002; flow rate 0.5 μl/h, 200 μl capacity; Durect, Cupertino, CA, USA) filled with nor-binaltorphimine (nor-BNI; 800 nmol/100 μl; Sigma-Aldrich, St. Louis, MO, USA), a KOR antagonist, or senktide (800 nmol/100 μl; synthesized at Kyoto University, Japan), an NK3R agonist, were surgically implanted into the abdominal cavity of female rats on day 20. Control animals were implanted with the pump filled with a vehicle (17 mM NaHCO3) in the same manner. The dose of senktide (4 nmol/h/40–110 g BW) was chosen in accordance with a previous study, in which continuous subcutaneous infusion of senktide (2400 nmol/h/20–35 kg BW) produced intermittent bursts of the GnRH pulse generator with corresponding LH pulses in goats [31]. An equimolar dose of nor-BNI was used. Female rats were housed in groups of three in plastic cages, and their body weights and vaginal openings were monitored daily. After vaginal opening, vaginal smears were examined daily to monitor estrous cyclicity. The first day when the cornified cells were dominant was designated as the day of the first vaginal estrus.

Effects of chronic intraperitoneal administration of KOR antagonist or NK3R agonist on pulsatile LH secretion in peripubertal rats

Female rats were weaned at day 20 and randomly assigned to one of three treatment groups: nor-BNI (n = 5), senktide (n = 4) and vehicle (n = 5). On day 29, blood samples (50 μl) were collected from the free-moving animals for 3 h at 6-min intervals, starting at 1300 h, through a silicone catheter inserted into the right atrium through the jugular vein on the previous day of blood sampling. An equivalent volume of rat red blood cells, taken from donor rats and diluted with heparinized saline, was replaced through the cannula after each blood collection to keep the hematocrit constant. Plasma was separated by immediate centrifugation and stored at −20°C until assayed for LH.

At the end of blood sampling, rats were sacrificed and ovaries and uteri were collected and weighed. Five hundred-microliter blood samples were also collected to determine plasma estradiol-17β levels.

LH and estradiol-17β assay

LH contents in 25-μl plasma samples were measured by a double antibody radioimmunoassay (RIA) using a rat LH RIA kit provided by the National Hormone and Peptide Program (Baltimore, MD, USA). Plasma LH concentrations were expressed in terms of the NIDDK rat LH RP-3. Values below the level of detectability for the assay were assigned the minimum detectable concentration of the assay. The least detectable level was 7.8 pg/tube, and the intra- and inter-assay coefficients of variation were 6.2% and 7.2% at 45 pg/
Estradiol-17β contents in 35-µl plasma samples were measured by electrochemiluminescence using ECLusys E2II kit (Roche Diagnostics Japan, Tokyo, Japan) in a commercial laboratory (SRL, Tokyo, Japan). Values below the level of detectability for the assay were assigned the minimum detectable concentration of the assay. The least detectable level was 0.35 pg/tube, and the intra- and inter-assay coefficients of variation were 4.5% and 3.1% at 1.26 pg/tube, respectively.

Data analysis

LH pulses were identified by the PULSAR computer program [32]. Mean LH concentrations and the frequency and amplitude of LH pulses were calculated for the 3-h sampling period in each individual. Averages of these parameters were then calculated for each group. Before statistical analysis, frequency of LH pulses was square-root transformed to normalize variability across a range of values. Statistical differences in the mean LH concentrations, in the frequency of LH pulses and in the age and body weight at vaginal opening and first estrus were determined by one-way ANOVA followed by the post hoc Tukey’s Honestly Significant Difference (HSD) test. Statistical differences in amplitude of LH pulses were not determined because only one vehicle-treated animal showed an LH pulse.

Results

Effects of chronic intraperitoneal administration of KOR antagonist or NK3R agonist on puberty onset

Chronic intraperitoneal infusion of nor-BNI, a KOR antagonist, between days 20 and 34 advanced vaginal opening and the first estrus. Half of the nor-BNI-treated animals showed the vaginal opening on day 29, whereas no vehicle-treated controls showed vaginal opening at this time (Fig. 1A). In addition, all individuals showed the first estrus by day 37, whereas no vehicle-treated controls showed first estrus at this time (Fig. 1B). The average age at vaginal opening tended to be younger in nor-BNI-treated animals (P=0.052, Tukey’s HSD test) than in the vehicle-treated controls (Fig. 1C), and the average age at first estrus was significantly younger in nor-BNI-treated animals (P<0.05, Tukey’s HSD test) than in the vehicle-treated controls (Fig. 1D). The nor-BNI treatment had no significant effect on the body weight at any age (Fig. 2A). The average body weight at vaginal opening (Fig. 2B) and first estrus (Fig. 2C) were significantly lower (P<0.05, Tukey’s HSD test) in nor-BNI-treated animals than in vehicle-treated controls.

Chronic intraperitoneal infusion of senktide, an NK3R agonist, also advanced the first estrus, but was slightly less effective than nor-BNI. Half of the senktide-treated animals showed the first estrus on day 37, when no vehicle-treated controls showed the first estrus (Fig. 1B). The average age (Fig. 1D) and body weight (Fig. 2C) at the first vaginal estrus were significantly younger (P<0.05, Tukey’s HSD test) in nor-BNI-treated animals than in vehicle-treated controls, respectively, but the age at vaginal opening was comparable to that in the vehicle-treated animals.

Chronic administration of nor-BNI tended to increase plasma estradiol levels and uterine weight, but both the nor-BNI and senktide treatments failed to show a significant effect on plasma estradiol levels and weights of ovaries and uteri at 29 days of age (Fig. 4).
The present study demonstrates that dynorphin-KOR signaling plays a critical inhibitory role in the pubertal restraint of GnRH/LH secretion in female rats, because chronic peripheral administration of nor-BNI, a KOR antagonist, advanced pulsatile LH secretion and hence puberty onset in developing female rats. Dynorphin neurons are abundantly distributed in several regions of the hypothalamus [19, 20] including the ARC, wherein dynorphin is coexpressed in a group of neurons with kisspeptin and NKB in mammals [16, 21–23]. Increasing evidence indicates that a group of ARC neurons, referred to as KNDy neurons [23], may play a critical role in a pulsatile GnRH secretion [16, 24]. Navarro et al. [21] showed that KOR mRNA was found in 20% of KNDy neurons in the ARC of female mice, suggesting that recurrent collaterals of KNDy neurons could signal through a dynorphin-KOR signaling pathway. Thus, dynorphin-KOR signaling in the ARC KNDy neurons, a putative intrinsic source for driving the GnRH pulse generator, may play a critical role in prepubertal restraint of GnRH/LH secretion. Recently, Navarro et al. [35] suggested that some other KOR-expressing interneurons (not
KNDy neurons) may mediate the action of dynorphin on GnRH pulse generation. Therefore, the current KOR antagonist may directly or indirectly act on ARC KNDy neurons to enhance GnRH/LH pulses in prepubertal rats. It is unlikely that the KOR antagonist directly acts on GnRH neurons, because previous studies showed few KOR expressions in rat GnRH neurons [33, 34]. Further studies are needed to clarify the site(s) of KOR antagonism, which advanced puberty onset in the present study.

The present study demonstrates that NKB-NK3R signaling also plays a role in regulating the pubertal increase in GnRH/LH secretion in normal developing female rats, because the administration of senktide, a NK3R agonist, advanced pulsatile LH secretion in 75% of animals and hence puberty onset in normal developing female rats. Navarro et al. [12] showed that repeated central administration of senktide advanced puberty onset in underfed female rats. Taken together with the facilitatory effect we found with senktide on LH pulses, the stimulatory role of NKB-NK3R signaling was at least partly involved in the increase in pubertal GnRH/LH secretion, and thus puberty onset, in normal developing rats as well as underfed rats. KNDy neurons have been reported to express KN3R in mammals including rats [20, 21, 36], suggesting that the current senktide may directly act KNDy neurons to advance puberty onset in female rats.

Based on the roles of dynorphin and NKB in gating pubertal initiation of GnRH/LH pulsatile secretion, we propose a possible mechanism for the pubertal activation of the GnRH/LH pulse generator in rats. The present study showed that the KOR antagonist had a more potent effect on relieving LH pulses from prepubertal restraint in female rats, compared with the NK3R agonist. This leads us to an assumption that the GnRH pulse generator may be mainly downregulated by inhibitory dynorphin-KOR signaling during the prepubertal period, rid of this inhibition at the onset of puberty and then upregulated by stimulatory input of NKB. This assumption is consistent with the previous finding that NK3R antagonist SB222200 administration had no effect on puberty onset in intact developing peripubertal female rats [12]. The present study used only a single dose of nor-BNI and senktide to evaluate the role of dynorphin and NKB signaling on the onset of puberty. A higher dose of senktide or other more potent NK3R agonists may overcome prepubertal restraint of GnRH/LH secretion. Several other issues need to be addressed, such as the effective doses, stability in circulation and binding affinity for its receptors. Future investigations are required to examine these issues.

The present results may lead to a chance to apply KOR antagonism and/or NK3R agonism to restore GnRH/LH secretion for patients bearing a hypogonadotropic hypogonadism. Exogenous gonadotropin therapy, the current major approach for human infertility, bears the risk of hyperstimulation of gonadal function, such as multiple follicular development leading to cycle cancellation, ovarian hyperstimulation syndrome and multiple pregnancies, all of which require intense monitoring of hormonal profiles. Administration of pulsatile GnRH is another therapeutic method for human infertility with a low risk of a multiple pregnancies. However, this method could be a burden on patients because of its methodological complexity, such as maintenance of an infusion pump attached to an intravenous or subcutaneous catheter. Thus, chronic administration of a KOR antagonist or NK3R agonist with a sustained-release capsule could be an alternative therapeutic approach for stimulating gonadal function based on the physiological function of GnRH/LH pulse generation.

In conclusion, the present study suggests that the inhibitory input of dynorphin on the ARC KNDy neurons plays a role in the prepubertal restraint of GnRH/LH secretion in normal developing female rats. The present study also suggests that attenuation of dynorphin-KOR signaling and an increase in NKB-NK3R signaling trigger the onset of puberty in normal developing female rats. This study expands our understanding of the mechanism controlling pubertal changes in GnRH/LH pulse generation and suggests a possible therapy comprised of KOR antagonism and/or NKB agonism, which restores GnRH/LH secretion in patients with a disruption in normal pulsatile GnRH/LH secretion.

Acknowledgments

The authors are indebted to the National Hormone and Peptide Program for the rat LH assay kit, and to Drs GR Merriam and KW Wachter for the PULSAR computer program. The RIA and LH pulse analyses were performed at the Nagoya University Radioisotope Center and the Information Technology Center, respectively. This study was supported in part by a grant from the Program for Promotion of Basic Research Activities for Innovative Biosciences (to KM), by the Research Program on Innovative Technologies for Animal Breeding, Reproduction and Vaccine Development (to HT) and by Grants-in-Aid from the Japan Society for the Promotion of Science No. 23380163 (to HT) and No. 23580402 (to YU).

References

1. Watanebe G, Terasawa E. In vivo release of luteinizing hormone releasing hormone increases with puberty in the female rhesus monkey. Endocrinology 1989; 125: 92–99. [Medline]
2. Sisk CL, Richardson HN, Chappell PE, Levine JI. In vivo gonadotropin-releasing hormone secretion in female rats during peripubertal development and on proestrus. Endocrinology 2001; 142: 2929–2936. [Medline]
3. Sisk CL, Foster DL. The neural basis of puberty and adolescence. Nat Neurosci 2004; 7: 1040–1047. [Medline]
4. Seminara SB, Messager S, Chatzidaki EE, Thresher RR, Acierno JS Jr, Shagoury JK, Bo-Abbas Y, Kuo Y, Whetzel L, Hendrick AG, Zahn D, Dixon J, Kaiser UB, Slaaenhaup S, Gussel GF, O’Rahilly S, Carlton MB, Crowley WF Jr, Apapio SA, Colledge WH. The GPR54 gene as a regulator of puberty. N Engl J Med 2003; 349: 1614–1627. [Medline]
5. de Roux N, Genin E, Carel JC, Matsuda F, Chausain JL, Milgrom E. Hypogonadotropic hypogonadism due to loss of function of the Kiss1-derived peptide receptor GPR54. Proc Natl Acad Sci USA 2003; 100: 10972–10976. [Medline]
6. Topaloglu AK, Reimann F, Gheu M, Yalin AS, Koton LD, Porter KM, Serin A, Mungan NO, Cook JR, Ozbek MN, Imamoglu S, Akalin NS, Yuksel B, O’Rahilly S, Senple RK, TAC3 and TACR3 mutations in familial hypogonadotropic hypogonadism reveal a key role for Neurokinin B in the central control of reproduction. Nat Genet 2009; 41: 354–358. [Medline]
7. Gianetti JM, Tuset C, Noel SD, Au MG, Dwyer AA, Hughes VA, Abreu AP, Carroll J, Truhrbach E, Silveira LF, Costa EM, de Mendonca BB, de Castro M, Lofrano A, Hall JE, Bolu E, Ozturk M, Quinton R, Amory JK, Stewart SE, Arlt W, Cole TR, Crowley WF, Kaiser UB, Latronico AC, Seminara SB, TAC3/TACR3 mutations reveal preferential activation of gonadotropin-releasing hormone release by neurokinin B in neonatal life followed by reversal in adulthood. J Clin Endocrinol Metab 2010; 95: 2857–2867. [Medline]
8. Young J, Boulland J, Francou B, Raffin-Sanson ML, Gailez S, Jeanpierre M, Gryenberg M, Kamenicky S, Jeanpierre M, Pech JF, Travers J, Thibodeau SB, Doyon-Sirois E, Milgrom E. The GPR54 gene as a regulator of puberty. Gut 2009; 57: 1614–1627. [Medline]
9. Navarro VM, Castellano JM, Fernandez-Fernandez R, Barreiro ML, Rao J, Sanchez-
Criado JE, Aguillar E, Dieguez C, Pinilla L, Tena-Sempere M. Developmental and hormonally regulated messenger ribonucleic acid expression of Kiss1-1 and its putative receptor, GPR54, in rat hypothalamus and potent luteinizing hormone-releasing activity of Kiss1-1 peptide. Endocrinology 2004; 145: 4565–4574. [Medline]

10. Takase K, Enoyama Y, Inoue N, Matsui H, Yamada S, Shimizu M, Homma T, Tsunikawa J, Kanda S, Matsumoto H, Oka Y, Tsukamura H, Maeda KI. Possible role of oestrogen in pubertal increase of Kiss1/kisspeptin expression in discrete hypothalamic areas of female rats. J Neuroendocrinol 2009; 21: 527–537. [Medline]

11. Gill JC, Navarro VM, Kwong C, Noel SD, Martin C, Xu S, Clifton DK, Carroll RS, Steiner RA, Kaiser UB. Increased neurokinin B (Tac2) expression in the mouse arcuate nucleus is an early marker of pubertal onset with differential sensitivity to sex steroid-negative feedback than Kiss1. Endocrinology 2012; 153: 4883–4893. [Medline]

12. Navarro VM, Ruiz-Pino F, Sanchez-Garrido MA, Garcia-Galiano D, Hobbis SJ, Manfredi-Lozano M, Leon S, Sangiao-Alverelles S, Castellano JM, Clifton DK, Pinilla L, Steiner RA, Tena-Sempere M. Role of neurokinin B in the control of female puberty and its modulation by metabolic status. J Neurosci 2012; 32: 2388–2397. [Medline]

13. Navarro VM, Fernandez-Fernandez R, Castellano JM, Roa J, Mayen A, Barreiro ML, Gaytan F, Aguilar E, Pinilla L, Dieguez C, Tena-Sempere M. Advanced vaginal opening and precocious activation of the reproductive axis by Kiss1-1 peptide, the endogenous ligand of GPR54. J Physiol 2004; 561: 379–386. [Medline]

14. Civelli O, Douglas J, Goldstein A, Herbert E. Sequence and expression of the rat prodynorphine gene. Proc Natl Acad Sci USA 1985; 82: 4291–4295.

15. Goodman RL, Coolen LM, Anderson GM, Hardy SL, Valient M, Connors JM, Fitzgerald ME, Lehman MN. Evidence that dynorphin plays a major role in mediating progesterone negative feedback on gonadotropin-releasing hormone neurons in sheep. Endocrinology 2004; 145: 2959–2967. [Medline]

16. Wakabayashi Y, Nakada T, Murata K, Ohkura S, Mogi K, Navarro VM, Clifton DK, Mori Y, Tsukamura H, Maeda K, Steiner RA, Okamura K. Neurokinin B and dynorphin A in kisspeptin neurons of the arcuate nucleus participate in generation of periodic oscillation of neural activity driving pulsatile gonadotropin-releasing hormone secretion in the goat. J Neurosci 2010; 30: 3124–3132. [Medline]

17. Maeda K, Ohkura S, Enoyama Y, Wakabayashi Y, Oka Y, Tsukamura H, Okamura H. Neurobiological mechanisms underlying GnRH pulse generation by the hypothalamus. Brain Res 2010; 1364: 103–115. [Medline]

18. Mostari MP, Ieda N, Deura C, Minabe S, Yamada S, Enoyama Y, Maeda KI, Tsukamura H. Dynorphin-kappa opioid receptor signaling partly mediates estrogen negative feedback effect on LH pulses in female rats. J Reprod Dev 2013; 59: 266–272. [Medline]

19. Simerly RB, McCaI LD, Watson SJ. Distribution of opioid peptides in the preoptic region: immunohistochemical evidence for a steroid-sensitive enkephalin sexual dimorphism. J Comp Neurol 1988; 276: 442–459. [Medline]

20. Burke MC, Letts PA, Krajewski SJ, Rance NE. Coexpression of dynorphin and neurokinin B in the hypothalamus in the rat hypothalamus: Morphologic evidence of interrelated function within the arcuate nucleus. J Comp Neurol 2006; 498: 712–726. [Medline]

21. Navarro VM, Gottsch ML, Chavkin C, Okamura H, Clifton DK, Steiner RA. Regulation of gonadotropin-releasing hormone secretion by kisspeptin/dynorphin/neurokinin B neurons in the arcuate nucleus of the mouse. J Neurosci 2009; 29: 11859–11866. [Medline]

22. Mittelman-Smith MA, Williams H, Krajewski-Hall SJ, Lai J, Cioli P, McMullen NT, Rance NE. Arcuate kisspeptin/neurokinin B/dynorphin (KNDy) neurons mediate the estrous suppression of gonadotropin secretion and body weight. Endocrinology 2012; 183: 2800–2812. [Medline]